Gastrointestinal Cancer | Specialty

Emerging Combos Lead to More Questions, Research Efforts in Advanced HCC

February 20th 2020

James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.

Nivolumab/Cabiralizumab Combo Misses PFS Endpoint in Pancreatic Cancer

February 19th 2020

The combination of nivolumab and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).

Immunotherapy Combos Emerging in HCC Armamentarium

February 18th 2020

Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.

Dr. Ilson on Investigative TKI Combinations in Gastric Cancer

February 18th 2020

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

Dr. Lockhart on Dual-Immunotherapy Strategies in CRC

February 18th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).

Researchers Forge Ahead Amid Setbacks in Advanced Gastric Cancer

February 17th 2020

David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.

Dr. O'Reilly on the Utility of PARP Inhibitors in Pancreatic Cancer

February 15th 2020

Eileen O'Reilly, MD, discusses the utility of PARP inhibitors in pancreatic cancer.

Genetic Testing, PARP Inhibitors Lead to Transformed Pancreatic Cancer Paradigm

February 15th 2020

Eileen O’Reilly, MD, reflects on the treatment advances that are expanding the pancreatic cancer paradigm.

Janjigian Highlights Lessons Learned from 2020 Gastrointestinal Cancers Symposium

February 14th 2020

Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.

Dr. Corcoran on Targeting HER2 Amplification in CRC

February 14th 2020

Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.

Expert Highlights Latest Developments in Early and Locally Advanced Pancreatic Cancer

February 14th 2020

Diane Simeone, MD, discusses recent data on neoadjuvant and adjuvant therapy for patients with locally advanced or resectable pancreatic cancer, and questions surrounding germline testing for earlier identification of this disease.

Investigators Test PARP Inhibitor in IDH-Mutant Solid Tumors

February 13th 2020

Investigators will challenge therapeutic convention by testing a PARP inhibitor instead of an IDH-targeted therapy in patients with metastatic IDH1/2-mutated glioma, cholangiocarcinoma, and other solid tumors that are refractory to standard treatment.

FDA Grants Ripretinib Priority Review for Advanced GIST

February 13th 2020

The FDA has granted a priority review designation to a new drug application for ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors.

Dr. Simeone on Impact of PARP Inhibitors on Pancreatic Cancer

February 13th 2020

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.

Dr. Abou-Alfa on Progress Made in Hepatocellular Carcinoma

February 11th 2020

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

February 11th 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Dr. Cercek on the Importance of Molecular Testing in CRC

February 8th 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Novel Therapeutic Targets and Combinations in mCRC

February 8th 2020

MCRC: Future Directions for Molecular-Driven Treatment

February 8th 2020

Immunotherapy for MSI-High/dMMR mCRC

February 8th 2020